The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Poly ICLC     [5-(4-amino-2-oxo-pyrimidin- 1-yl)-3,4...

Synonyms: NSC-301463, AC1L8SGX, NSC301463, 34354-71-7, Poly-IC-poly-L-lysine
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC301463


High impact information on NSC301463


Biological context of NSC301463

  • The cellular mechanism of the increased radiosensitivity caused by Poly (ICLC) was reflected in the reduction of the width of the shoulder on the cell survival curve, which was dependent on the dose of the drug [10].

Anatomical context of NSC301463

  • Poly ICLC did not induce DNA synthesis in subconfluent, quiescent or in confluent, quiescent fibroblasts under serum-free conditions [6].

Associations of NSC301463 with other chemical compounds

  • Of the five BRMs tested, MVE-2, Poly ICLC, OK-432, and alpha beta IFN were capable of stimulating both natural killer (NK) cell and macrophage (M phi) tumoricidal activity, whereas BM 41-332 augmented only NK cells [11].

Gene context of NSC301463


Analytical, diagnostic and therapeutic context of NSC301463


  1. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Ewel, C.H., Urba, W.J., Kopp, W.C., Smith, J.W., Steis, R.G., Rossio, J.L., Longo, D.L., Jones, M.J., Alvord, W.G., Pinsky, C.M. Cancer Res. (1992) [Pubmed]
  2. Poly ICLC in the treatment of postinfectious demyelinating encephalomyelitis. Salazar, A.M., Engel, W.K., Levy, H.B. Arch. Neurol. (1981) [Pubmed]
  3. Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits. Gatmaitan, B.G., Legaspi, R.C., Levy, H.B., Lerner, A.M. Antimicrob. Agents Chemother. (1980) [Pubmed]
  4. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Giantonio, B.J., Hochster, H., Blum, R., Wiernik, P.H., Hudes, G.R., Kirkwood, J., Trump, D., Oken, M.M. Investigational new drugs. (2001) [Pubmed]
  5. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Wong, J.P., Nagata, L.P., Christopher, M.E., Salazar, A.M., Dale, R.M. Vaccine (2005) [Pubmed]
  6. Double-stranded RNA regulation of DNA synthesis in fibroblasts. Perricone, M.A., Giri, S.N., Hyde, D.M. Exp. Cell Res. (1992) [Pubmed]
  7. Studies on hepatic oxidative stress and antioxidant defence system during chloroquine/poly ICLC treatment of Plasmodium yoelii nigeriensis infected mice. Siddiqi, N.J., Puri, S.K., Dutta, G.P., Maheshwari, R.K., Pandey, V.C. Mol. Cell. Biochem. (1999) [Pubmed]
  8. Changes in leukocyte recirculation, NK cell activity, and HLA-DR expression in peripheral blood mononuclear cells of MS patients treated with Poly ICLC. Bever, C.T., Jacobson, S., Mingioli, E.S., McFarland, H.F., McFarlin, D.E., Levy, H.B. Int. J. Immunopharmacol. (1991) [Pubmed]
  9. Immune response modifying activity in mice of polyinosinic: polycytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly-ICLC]. Chirigos, M.A., Papademetriou, V., Bartocci, A., Read, E., Levy, H.B. Int. J. Immunopharmacol. (1981) [Pubmed]
  10. Tumor response to interferon inducer and radiation effect of serum interferon levels. Lvovsky, E.A., D'Souza, J., Eng, D., D'Souza, D., Lvovsky, B., Hetland, R., Craver, W.L., Sobel, S.H. J. Biol. Regul. Homeost. Agents (1988) [Pubmed]
  11. Biological response modifiers: regulators of the cellular immune system and adjuvants in antitumor therapy. Chirigos, M.A., Schlick, E., Saito, T., Gruys, E. Methods and findings in experimental and clinical pharmacology. (1986) [Pubmed]
  12. Poly ICLC induces anti-IC antibodies in mice and rabbits. Granados, E.N., Alm, T., O'Malley, J.A., McGarry, M., Bello, J. J. Interferon Res. (1984) [Pubmed]
  13. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Wong, J.P., Yang, H., Nagata, L., Kende, M., Levy, H., Schnell, G., Blasetti, K. Vaccine (1999) [Pubmed]
WikiGenes - Universities